is semaglutide a generic drug shot available for Rs 1,296 per month: Top diabetologists welcome cost cut with word of caution India's Dr Reddy's plans to
Description
Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)
It needs to be administered with care though
Schedule a consultation today!
GLP-3 RT is a next-generation triple hormone agonist hitting the GLP-1, GIP, and glucagon receptors at once researched as one of the most powerful
Expanding global access to affordable metabolic care
